Quarterly Financial Data (Details) - USD ($) $ / shares in Units, shares in Millions	3 Months Ended																12 Months Ended
	Jun. 27, 2015		Mar. 28, 2015		Dec. 27, 2014		Sep. 27, 2014		Jun. 28, 2014		Mar. 29, 2014		Dec. 28, 2013		Sep. 28, 2013		Jun. 27, 2015		Jun. 28, 2014		Jun. 29, 2013
Net sales	$ 1,531,600,000		$ 1,049,100,000		$ 1,071,700,000		$ 951,500,000		$ 1,144,200,000		$ 1,004,200,000		$ 979,000,000		$ 933,400,000		$ 4,603,900,000	[1]	$ 4,060,800,000	[1]	$ 3,539,800,000	[1]
Gross profit	628,100,000		378,800,000		383,800,000		321,800,000		415,700,000		315,000,000		360,700,000		356,300,000		1,712,500,000		1,447,700,000		1,280,000,000
Net income	$ 56,400,000	[2]	$ (94,900,000)	[3]	$ 70,200,000	[4]	$ 96,300,000	[5]	$ 131,700,000	[6]	$ 48,100,000	[7]	$ (86,000,000)	[8]	$ 111,400,000	[9]	$ 128,000,000		$ 205,300,000		$ 441,900,000
Earnings (loss) per share:
Earnings Per Share, Basic	$ 0.39	[2],[10]	$ (0.67)	[3],[10]	$ 0.52	[4],[10]	$ 0.72	[5],[10]	$ 0.98	[6],[10]	$ 0.36	[7],[10]	$ (0.87)	[8],[10]	$ 1.18	[9],[10]	$ 0.92		$ 1.78		$ 4.71
Earnings Per Share, Diluted	$ 0.38	[2],[10]	$ (0.67)	[3],[10]	$ 0.51	[4],[10]	$ 0.72	[5],[10]	$ 0.98	[6],[10]	$ 0.36	[7],[10]	$ (0.87)	[8],[10]	$ 1.18	[9],[10]	$ 0.92		$ 1.77		$ 4.68
Weighted average shares outstanding
Basic	146.3		140.8		136.3		133.9		133.8		133.7		98.7		94.2		139.3		115.1		93.9
Diluted	146.8		140.8		136.8		134.4		134.3		134.3		98.7		94.7		139.8		115.6		94.5
Selected Quarterly Financial Information [Abstract]
Business Acquisition, Transaction Costs											$ 3,200,000		$ 103,200,000		$ 12,000,000
Litigation Settlement, Expense			$ 2,000,000												2,500,000
Acquisition Costs, Period Cost															$ 1,900,000
Goodwill impairment charge	$ 6,800,000																$ 6,800,000		$ 0		$ 0
Derivative, Loss on Derivative	5,500,000		258,200,000		$ 64,700,000												326,400,000		0		0
Net loss from equity method investment	3,500,000				3,000,000		$ 3,100,000										(9,900,000)		(8,700,000)
Investment distribution							1,200,000
Proceeds from Collaborators					12,500,000
Inventory Step-up	15,600,000
Cost of Services, Licenses and Maintenance Agreements	18,000,000				10,000,000
Restructuring			1,100,000		2,400,000		1,700,000		$ 10,500,000		19,500,000		14,900,000				5,100,000		47,000,000		2,900,000
Legal Fees	13,400,000
Business Combination, Acquisition Related Costs	18,500,000		2,000,000		17,800,000		$ 1,100,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability											$ 5,800,000		4,900,000
Total loss on extinguishment of debt					$ 9,600,000								(165,800,000)				(10,500,000)		(165,800,000)		$ 0
Write-off of in-process research and development													6,000,000
Texas Medicaid [Member]
Selected Quarterly Financial Information [Abstract]
Loss Contingency Accrual	$ 15,000,000		9,000,000						$ 15,000,000								$ 15,000,000		$ 15,000,000
Omega [Member]
Selected Quarterly Financial Information [Abstract]
Business Combination, Acquisition Related Costs			$ 18,600,000
Extinguishment of Debt, Type [Domain]
Selected Quarterly Financial Information [Abstract]
Total loss on extinguishment of debt													$ 165,800,000

[1] Amounts may not cross-foot due to rounding.

[2] Includes legal and consulting fees related to our defense against Mylan N.V. of $13.4 million, acquisition costs of $18.5 million, goodwill impairment of $6.8 million, losses on derivatives terminated with extinguishment of associated debt and associated with hedging the pending GSK acquisition of $5.5 million, losses on equity method investments of $3.5 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and an initial payment made in connection with an R&D agreement of $18.0 million.

[3] Includes acquisition costs totaling $2.0 million, an increase in litigation accrual of $2.0 million, restructuring charges of $1.1 million, Omega financing fees of $18.6 million, and losses on derivatives associated with the Omega acquisition of $258.2 million.

[4] Includes restructuring charges of $2.4 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, Omega transaction expenses of $17.8 million, losses on derivatives associated with the Omega acquisition of $64.7 million, equity method investment losses of $3.0 million, income from transfer of rights agreement of $12.5 million, and $9.6 million loss on extinguishment of debt.

[5] Includes acquisition costs of $1.1 million, restructuring charges of $1.7 million, equity method investment losses of $3.1 million, and a $1.2 million investment distribution.

[6] Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.

[7] Includes restructuring charges totaling $19.5 million, write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs.

[8] Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, restructuring charges totaling $14.9 million, write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D totaling $6.0 million related to Paddock and Rosemont.

[9] Includes Elan transactions costs of $12.0 million, litigation settlement of $2.5 million, and acquisition costs of $1.9 million.

[10] The sum of individual per share amounts may not equal due to rounding.